Lake Street Capital Initiates Coverage on Yield10 Bioscience (NASDAQ:YTEN)

Research analysts at Lake Street Capital assumed coverage on shares of Yield10 Bioscience (NASDAQ:YTENGet Rating) in a report released on Thursday, The Fly reports. The firm set a “buy” rating and a $12.00 price target on the specialty chemicals company’s stock. Lake Street Capital’s price target would indicate a potential upside of 255.03% from the company’s previous close.

Several other brokerages have also issued reports on YTEN. Zacks Investment Research upgraded shares of Yield10 Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday, April 12th. Maxim Group lowered their price objective on shares of Yield10 Bioscience from $18.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, March 10th.

Shares of Yield10 Bioscience stock opened at $3.38 on Thursday. Yield10 Bioscience has a 1 year low of $3.25 and a 1 year high of $10.89. The firm has a market cap of $16.54 million, a PE ratio of -1.44 and a beta of 1.33. The company has a 50 day simple moving average of $4.41 and a two-hundred day simple moving average of $4.77.

Yield10 Bioscience (NASDAQ:YTENGet Rating) last announced its earnings results on Wednesday, March 9th. The specialty chemicals company reported ($0.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.03. Yield10 Bioscience had a negative net margin of 1,796.58% and a negative return on equity of 56.52%. The business had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. During the same period in the previous year, the business posted ($0.79) earnings per share. Analysts anticipate that Yield10 Bioscience will post -2.87 EPS for the current year.

A hedge fund recently raised its stake in Yield10 Bioscience stock. Geode Capital Management LLC increased its position in Yield10 Bioscience, Inc. (NASDAQ:YTENGet Rating) by 18.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,433 shares of the specialty chemicals company’s stock after buying an additional 6,243 shares during the quarter. Geode Capital Management LLC owned 0.81% of Yield10 Bioscience worth $239,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 19.28% of the company’s stock.

About Yield10 Bioscience (Get Rating)

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing oilseed Camelina to produce proprietary products; and high value seed traits for the agriculture and food industries.

See Also

The Fly logo

Receive News & Ratings for Yield10 Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Yield10 Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.